Assessment of the Clinical Utility of the NETest in a US Registry-Based Study Abstract #2202

Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.
Aim(s): We evaluated the usefulness of a blood-based multigene biomarker assay in the management of neuroendocrine tumor disease (NETs) in a real-world study of a USA registry (RegisterNET: NCT02270567) of 100 patients. The NET liquid biopsy was investigated for diagnostic accuracy, and prediction of clinical disease status in 2 cohorts (treated and watch-and-wait).
Materials and methods: NET subjects (n=100) followed for 6 months. Gastroenteropancreatic (68%); lung 20%, and unknown origin (12%).Well-differentiated, low grade (97%), stage IV (96%); 70% had surgery; 56% drug treatment. NETest was measured at each visit and disease status was determined by RECIST. Scores categorized as low (NETest <40%) or high (>80%) defined disease as stable or progressive.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Professor Mark Kidd

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland
Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr.med. Alexander Siebenhüner
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#2913 The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent ‘Real-World’ Validation Study
Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Mark van Treijen
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd